Abbott Labs (ABT) Offering Possible 7.45% Return Over the Next 30 Calendar Days

Abbott Labs's most recent trend suggests a bullish bias. One trading opportunity on Abbott Labs is a Bull Put Spread using a strike $105.00 short put and a strike $97.50 long put offers a potential 7.45% return on risk over the next 30 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $105.00 by expiration. The full premium credit of $0.52 would be kept by the premium seller. The risk of $6.98 would be incurred if the stock dropped below the $97.50 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Abbott Labs is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Abbott Labs is bullish.

The RSI indicator is at 60.73 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Abbott Labs

CORRECTED-U.S. government to send out over 7 million Abbott BinaxNOW tests this week
Mon, 16 Nov 2020 16:56:02 +0000
The U.S. government will send over 7 million of Abbott Laboratories' BinaxNOW rapid antigen tests for COVID-19 to states, hospice providers, and for other uses this week, a top administration official said at a press briefing on Monday. In addition to the more than 7 million tests being distributed, the agency will have 820,000 tests remaining for any unanticipated emergency testing demands that could arise as COVID-19 cases spike around the country. The U.S. Department of Health and Human Services will push the U.S. Food and Drug Administration to review COVID-19 tests developed by universities, said Admiral Brett Giroir, assistant secretary for health at the U.S. Department of Health and Human Services.

Abbott Named Industry Sustainability Leader for the Eighth Year in a Row on the Dow Jones Sustainability Index (DJSI)
Mon, 16 Nov 2020 15:20:00 +0000
For the eighth consecutive year, Abbott (NYSE: ABT) has been named the industry leader in sustainability by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability. As the Global Industry Leader in the Health Care Equipment & Supplies sector, the company earned top scores for governance/economic and social performance. This is the 16th consecutive year that Abbott has been recognized as a sustainability leader through its inclusion on the DJSI, including both the Dow Jones Sustainability World Index and North America Index.

Top 10 Stocks Billionaire Ray Dalio Just Bought
Mon, 16 Nov 2020 02:51:58 +0000
In this article we present the list of Top 10 Stocks Billionaire Ray Dalio Just Bought. Click to skip ahead and see the Top 5 Stocks Billionaire Ray Dalio Just Bought. Ray Dalio is the billionaire Founder, Co-Chairman and Co-Chief Investment Officer of Bridgewater Associates, the largest hedge fund in the world with over $140 billion […]

Forget Snowflake! Buy This Ultra-High-Growth Stock
Sat, 14 Nov 2020 14:08:00 +0000
Investors have understandably bid up shares of companies that deliver software as a service this year as those companies continue to benefit from a work-from-home world. For an example, we need only to look at the initial public offering of cloud-based data and analytics company Snowflake (NYSE: SNOW) — its shares more than doubled on its first day of trading in September. For instance, of the 463 million people with diabetes worldwide, only 25% are receiving care for the disease.

Abbott Labs, Intuitive Surgical Headline 5 Top Stocks Near Buy Points
Sat, 14 Nov 2020 13:00:18 +0000
Intuitive Surgical and Abbott Labs are among 5 top stocks near buy points as the market moves on coronavirus hopes and fears.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.